Effect of Guilong Kechuanning Tablets Combine with Antibiotic Drugs on Pulmonary Infection after Chemotherapy in Patients with Lung Cancer / 现代生物医学进展
Progress in Modern Biomedicine
;
(24): 5271-5274, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-615130
ABSTRACT
Objective:
To investigate the effect ofGuilong Kechuanning tablets combine with antibiotic drugs on pulmonary infection after chemotherapy in patients with lung cancer,so as to reduce the incidence of pulmonary infection in hospital.Methods:
A total of 120 patients with lung cancer complicated with pulmonary infection,who underwent chemotherapy in Baoji Hospital of Traditional Chinese Medicine from August 2013 to August 2015,were selected and randomly divided into control group (n=60) and experiment group (n=60).The control group was treated with Ceftizoxime,based on which,the experiment group was added oral Guilong Kechuanning tablets.The course oftreatment of the two groups was 2 weeks.Inflammation indicators of the two groups were compared before and after treatment,and the clinical effect,hospitalized time,antifebrile time,time significantly reduced of cough and expectoration,disappearance time of lung rales and the pulmonary bacterial clearance rate were observed between the two groups.Results:
The total effective rate (91.67%) of experiment group was significantly higher than that(73.33%) of control group (x2=13.121,P=0.004).Before treatment,there were no significant differences in WBC,CRP and NEUT levels between the two groups (P>0.05);while after treatment,the levels of WBC,CRP and NEUT were all lower than those before treatment in both groups (all P<0.05),and the levels of WBC,CRP and NEUT in the experiment group were lower than those in the control group(P<0.05).After treatment,the bacterial clearance rate (99.09%) of the experiment group was significantly higher than that (86.94%) of the control group (x2=54.876,P=0.000).Conclusion:
Guilong Kechuanning tablets combined with antibiotic drugs can effectively control the pulmonary infection after chemotherapy in the patients with lung cancer,and can improve the clinical symptoms and inflammatory reaction,which is worthy of clinical application.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Progress in Modern Biomedicine
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS